Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Business Results
May 16, 2005
- NEW PRODUCTS
May 16, 2005
- Daiichi: Ethical Drug Sales Up 2.4% to \311,844 Mil.
May 16, 2005
- BUSINESS NEWS IN BRIEF
May 16, 2005
- Largest Number of Consultations Requested by US Ventures: JETRO
May 16, 2005
- Towa Seeking Partnership to Build Marketing Route to Major Hospitals
May 16, 2005
- Wave of Buy-outs Unlikely in Japan: Mr Mikel of IMS Health
May 16, 2005
- Terumo Aiming for Sales of \300 Bil. in FY2007
May 16, 2005
- NEW PRODUCTS
May 16, 2005
- NBI Reaffirms Sales Target of \100 Bil. for FY2005
May 16, 2005
- SUEVEY
May 16, 2005
- Shionogi to Focus on Pain and Metabolic Syndrome in Addition to Infections
May 16, 2005
- PMDA Announces Provisional Measures to Improve Clinical Trial Consultation
May 16, 2005
- Mitsubishi Chemical, Mitsubishi Pharma to Come under New Holding Company
May 16, 2005
- JASMO Announces FY2005 Plans of Action
May 16, 2005
- MEDICAL DEVICE NEWS IN BRIEF
May 16, 2005
- 5th Bio Business Competition Japan
May 16, 2005
- R&D NEWS IN BRIEF
May 16, 2005
- WEBSITE NEWS
May 16, 2005
- REGULATORY NEWS IN BRIEF
May 16, 2005
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…